butenafine has been researched along with Leishmaniasis, Diffuse Cutaneous in 1 studies
butenafine: studied on experimental dermatophytosis
butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.
Leishmaniasis, Diffuse Cutaneous: A form of LEISHMANIASIS, CUTANEOUS caused by Leishmania aethiopica in Ethiopia and Kenya, L. pifanoi in Venezuela, L. braziliensis in South America, and L. mexicana in Central America. This disease is characterized by massive dissemination of skin lesions without visceral involvement.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezerra-Souza, A | 1 |
| Yamamoto, ES | 1 |
| Laurenti, MD | 1 |
| Ribeiro, SP | 1 |
| Passero, LF | 1 |
1 other study available for butenafine and Leishmaniasis, Diffuse Cutaneous
| Article | Year |
|---|---|
The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Benzylamines; Drug Repositioning; Female; Leishman | 2016 |